Vas Narasimhan

New Capabilities

Leading Novartis as it responds to the safety reports

Nine children who received Zolgensma, a one-time gene therapy for spinal muscular atrophy, later developed tumors. In two of the three cases tested, Novartis found evidence the virus used to deliver the treatment had inserted itself into the patient's DNA.

Updated 5 days ago

Money Moves

As of September 2026: Leading company through back-to-back clinical setbacks

Novartis' experimental muscle-disease drug del-desiran failed its phase 3 Harbor trial, missing the primary endpoint and sending shares down. The drug was the centerpiece of the company's $12 billion acquisition of Avidity Biosciences, which closed last year.

Updated Sep 8